‘Global Anti-Epilepsy Drugs Market Worth $5.1bn In 2021’ Says Visiongain Report

20 August 2018
Pharma

Visiongain’s new report Global Anti-Epilepsy Drugs Market Forecast 2017-2027: first-generation drugs, second-generation drugs, third-generation drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin indicates that the global anti-epilepsy drugs market will see $5.1bn in spending in 2021.
The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

The lead analyst of the report said: “In 2016, the global Anti-Epilepsy Drugs Market was valued at $4.3bn. The market is anticipated to grow at a CAGR of 4.4% to reach $6.9bn in 2027. Currently, the market is dominated by second-generation drugs. However, third-generation drugs are set to see the fastest growth during forecast period.

In 2016, the Epilepsy market was dominated by the US with a share of 47.5%. The market is expected to experience a high growth rate because of the increasing number of epilepsy patients in this region and increasing initiatives by the CDC to manage epilepsy.”

The 145-page report contains 100 charts that add visual analysis in order to explain the developing trends within the Global Anti-Epilepsy Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs and Others. This report also discusses the leading anti-epilepsy drugs and selected pipeline molecules.

The 145-page report offers market forecasts and analysis for the US, Japan, EU5, BRIC and RoW. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the anti-epilepsy drugs market. Moreover, this report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK. This report also covers pricing and reimbursement overview of the anti-epilepsy drugs market

The Global Anti-Epilepsy Drugs Market Forecast 2017-2027: first-generation drugs, second-generation drugs, third-generation drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin report will be of value to anyone who wants to better understand the anti-epilepsy drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the anti-epilepsy drugs industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever